Molex, a parent to Phillips Medisize, closes the acquisition of Vectura Group Ltd.
RT’s Three Key Takeaways:
- Acquisition Expands Inhalation Drug Delivery Capabilities: With the acquisition of Vectura, Phillips Medisize broadens its offerings to include expertise in dry powder inhalers, metered dose inhalers, nasal inhalers, and nebulizers, along with proprietary platforms like the Gyrohaler and Fox device.
- Enhanced End-to-End Services: The addition of Vectura strengthens Phillips Medisize’s capabilities in pharmaceutical analysis, process development, clinical trial supplies, and regulatory support, enabling comprehensive development and manufacturing solutions for pharmaceutical customers.
- Focus on Chronic Respiratory and Non-Respiratory Therapies: The partnership positions Phillips Medisize to meet the global demand for innovative therapies targeting conditions like asthma and COPD, as well as other non-respiratory diseases, according to the company.
Molex, a parent to Phillips Medisize, announced that it has completed, through an affiliate, the previously announced acquisition of Vectura Group Ltd from Vectura Fertin Pharma Inc, a subsidiary of Philip Morris International Inc.
Phillips Medisize is a manufacturer of products for pharmaceutical drug delivery, in vitro diagnostic and medtech markets. With the addition of Vectura, the company now offers a wider range of formulation, device design, combination product development, and manufacturing services.
The transaction includes Vectura’s proprietary technology and combination product development expertise in dry powder inhalers, including the lever operated multi-dose inhaler and Gyrohaler platforms; metered dose inhalers; nasal inhalers; and nebulizers, including the Fox device. Vectura also offers pharmaceutical analysis, process development, technical transfer, clinical trial supplies, and regulatory services.
“Phillips Medisize will continue to expand the services we offer pharmaceutical companies thanks to the acquisition of Vectura, particularly in inhalation, to help meet growing patient needs,” says Paul Chaffin, president of Phillips Medisize, in a release. “Together Phillips Medisize and Vectura are uniquely positioned to collaborate with leading pharmaceutical customers to develop innovative products that address the growing global demand for new therapies to treat chronic respiratory diseases like asthma and COPD, as well as non-respiratory conditions.”
Geraldine Venthoye, who has been appointed chief scientific officer and vice president for the Phillips Medisize Medical business, adds in a release, “We are excited about the opportunities and scale of Phillips Medisize, which will allow us to deliver our formulation and combination product expertise to more pharmaceutical customers as part of end-to-end pharmaceutical development.”
ID 60933364 © Pichetw | Dreamstime.com
